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Abstract: Since Cahan (1960) reported the first 48 cases that
successfully underwent lobectomy with regional lymph node dis-
section, which was called “radical lobectomy”, this procedure was
universally accepted and has remained a standard surgery for lung
cancer. In recent decades, the intrathoracic reevaluation of disease at
thoracotomy for lung cancer has evolved into a detailed and sophis-
ticated assessment of disease extent. Central to this is an evaluation
of nodal involvement at the mediastinal and hilar levels. This
technique, termed “systematic nodal dissection” (SND), has been
accepted by the IASLC to be an important component of intrathoracic
staging. In this manuscript, the significance, recent strategy, and tech-
nique of lymph node dissection for lung cancer are described.
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In 1951, Cahan et al.1 suggested that pneumonectomy withregional lymph node dissection should be a routine proce-
dure for lung cancer. Then in 1960, Cahan reported the first
48 cases that successfully underwent lobectomy with regional
lymph node dissection, which was called “radical lobectomy.”2
Since then, this procedure was universally accepted and has
remained a standard surgery for lung cancer. The descriptions of
mediastinal lymph node dissection in Cahan’s reports were very
similar to our routine lymph node dissection today.1,2
In recent decades, the intrathoracic reevaluation of
disease at thoracotomy for lung cancer has evolved into a
detailed and sophisticated assessment of disease extent. Cen-
tral to this is an evaluation of nodal involvement at the
mediastinal and hilar levels. This technique, now termed
“systematic nodal dissection (SND),” has been accepted by
the International Association for the Study of Lung Cancer
(IASLC) to be an important component of intrathoracic
staging.3 The consensus for SND could unify the nomencla-
ture and establish the minimal technical requirements for
nodal dissection in lung cancer surgery. In this article, the
significance, recent strategy, and technique of lymph node
dissection for lung cancer are described.
Definition of Lymph Node Dissection
First, the definition of “lymph node dissection” should
be reconfirmed. “Dissection” means to remove the tissue
from adjacent organs and skeletonize the anatomic structures.
Thus, “lymph node dissection” means the en block removal
of all tissue that may contain cancer cells, including the
lymph nodes and surrounding fatty tissue within anatomic
landmarks such as the trachea, bronchus, superior vena cava,
and the aorta and its branches, pulmonary vessels, and peri-
cardium (Figures 1A, B). European Society of Thoracic Sur-
geons guidelines have defined that the aim of SND is to
dissect and remove all mediastinal tissue containing the
lymph nodes within anatomic landmarks.4 Excision of at least
three mediastinal nodal stations, including the subcarinal
node, is recommended as a minimum requirement.4 The
nodes are separately labeled and histologically examined
after dissection according to recommendations for processing
and reporting of lymph node specimens.5
In addition, “sampling” means a lesser excision of certain
nodal stations that seem to be representative or abnormal in
preoperative evaluations or intraoperative findings (Figure 1C).
Doddoli et al.,6 Gajra et al.7 and Massard et al.8 suggested that
sampling was inferior to SND in terms of proper staging. The
term “systematic sampling” refers to a routine biopsy of lymph
nodes at some levels of nodal station.4,9 Keller et al.9 and Gajra
et al.7 reported that systematic sampling was as effective as SND
for accurately staging patients.
The Significance of Lymph Node Dissection
The significance of lymph node dissection can be dis-
cussed from two clinical aspects, accurate staging and sur-
vival benefit.
Accurate Staging
Surgeons have long been aware that the situation at
thoracotomy is not always as predicted by preoperative in-
vestigations. Several studies have shown that the sensitivity
and specificity for computed tomography (CT) in assessing
mediastinal nodal involvement is on the order of 52 to 79%
and 69 to 78%, respectively.10,11 Although positron emission
tomography is considered to be the most sensitive and accu-
rate investigation for screening of lymph node involvement,
with a sensitivity of 79 to 85% and specificity of 90 to 91%
in a meta-analysis,12 the assessment of nodal status by
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positron emission tomography is not reliable in patients with
microscopic nodal metastasis. Therefore, the intrathoracic
evaluation of nodal involvement at the mediastinal and hilar
levels during thoracotomy is considered to be an important
component of the staging process.13
This technique was termed SND by the IASLC staging
committee task force in 1996.3 In the task force, the term
“radical” was discarded as inferring some therapeutic benefit
from this evaluation. The term “mediastinal” was also dis-
carded because it might fail to recognize the importance of
the evaluation of N1 nodes. Graham et al.14 suggested that
SND could disclose “unexpected” N2 disease irrespective of
cell type, size, and location of the primary tumor, regardless
of whether prior mediastinoscopy had been performed. In
patients with adenocarcinomas, 60% of cN1 disease diag-
nosed by chest CT was histologically revealed to be N2
disease after thoracotomy.15 Even small-sized lung cancer
less than 2 cm in size shows hilar and mediastinal nodal
disease with an incidence of more than 20%.16,17 Further-
more, lung cancer has a phenomenon termed “skip metasta-
sis” consisting of N2 disease without N1 involvement with
the incidence of 20 to 38% in N2 patients.18–22 These facts
indicate the significance of SND at the mediastinal and hilar
levels during thoracotomy.
Among many clinicopathological factors, the patho-
logic nodal status is reported to be the most significant
prognostic factor.23,24 Pathologic examination of dissected
lymph nodes offers the most precise information for progno-
sis in patients with lung cancer. Furthermore, the recent
results of some multi-institutional clinical trials evaluating
the significance of adjuvant chemotherapy in patients with
lung cancer showed the survival benefit of postoperative
chemotherapy for node-positive patients.25,26 Ferguson27 re-
ported the results of meta-analysis evaluating the cost-effec-
tiveness of surgery for “unsuspected N2.” He suggested that
delaying resection until after completion of neoadjuvant ther-
apy provided the best survival and was more cost-effective
for unsuspected N2 patients. The accurate identification of
positive nodes leads to selection of the optimal therapy and
suggests the prognosis for each patient.6,7
For the aforementioned reasons, an accurate pathologic
assessment for metastasis of the lymph nodes is thought to
have many advantages for those with lung cancer. Therefore,
SND remains an important investigative process in all pa-
tients coming to surgery for lung cancer.28
Survival Benefit
Others have gone further, suggesting that cure rates
could be improved by lymph node dissection. Keller et al.9
reported the comparison of survival between patients with
resected stage II–IIIa non-small cell lung cancer who under-
went SND and systematic sampling. This nonrandomized
study showed that SND significantly improved the survival of
patients with stage II–IIIa non-small cell lung cancer. More-
over, some other retrospective studies have shown the sur-
vival benefit of nodal dissection.29–33 The survival benefit of
lymph node dissection for patients with lung cancer, how-
ever, has not been statistically clear, simply because few
prospective randomized controlled trials (RCTs) have been
conducted comparing SND with nodal sampling (Table
1).34–36 Izbicki et al.34 reported no significant difference in
FIGURE 1. The differences in the extent of nodal dissection
and sampling demonstrated on computed tomography (CT)
images. A, Pretracheal lymph nodes and surrounding fatty
tissue in the superior mediastinum. B, The extent of lymph
node dissection. C, The extent of lymph node sampling.
SVC, superior vena cava; LN, pretracheal lymph node.
TABLE 1. Previous Reports of Prospective Randomized Trials Comparing Systematic Nodal Dissection and Nodal Sampling
Author
Reported
Year
Years
Analyzed
Detailed Description
of Randomization
Method
Intention-
to-Treat
Analysis Patients
No. of Patients
(SND/Sampling)
Median
Follow-Up
(Months)
Overall Survival
(SND/Sampling)
Disease
Free
Survival
Izbicki 1998 NA Yes No Operable NSCLC 169 (76/93) 47.5 HR 0.76, p  0.273 HR 0.82,
p  0.338
Sugi 1998 1985–1992 No No Peripheral NSCLC
less than 2 cm
in size
115 (59/56) 65 5-yr survival 81.4%/
83.9%, p  NS
NA
Wu 2002 1989–1995 No No Clinical stage
I–IIIA NSCLC
471 (240/231) NA 5-yr survival 48.4%/
37.0%, p  0.0000
NA
NSCLC, non-small cell lung cancer; HR, hazard ratio; SND, systematic nodal dissection; NA, not applicable.
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survival between the patients with clinical stage I–IIIA lung
cancer who underwent SND and nodal sampling. However,
the number of enrolled patients in each arm (SND versus
sampling; n  76 versus 93) might have been insufficient
because more than half of the subjects were node-negative
patients in the pathologic examination. In a subgroup analy-
sis, they suggested a borderline effect of SND on overall
survival (p  0.058) in patients with pN1 or pN2 disease.34
Sugi et al.35 reported no significant difference in survival
between patients with peripheral cancer less than 2 cm who
underwent mediastinal dissection and sampling. However,
the number of enrolled patients in that study (SND versus
sampling; n  59 versus 56) was much less than that of the
study by Izbicki. Wu et al.36 reported the results of a pro-
spective randomized trial with 532 patients and suggested
that the SND group (n  268) showed significantly better
survival compared with the sampling group (n  264). This
study has been the only randomized study to suggest the
survival benefit of nodal dissection. Wright et al.37 reported
the results of meta-analysis of these three randomized RCTs
comparing SND and sampling. There was a significant re-
duction in the risk of death in the group undergoing SND with
a hazard ratio estimated at 0.78 (95% CI 0.65–0.93; p 
0.005). Detterbeck38 used the term “surprise N2” for micro-
scopic N2 disease, and reviewed the intraoperative manage-
ment of patients with “surprise N2.” Based on the results of
these randomized studies, he concluded that resection was
justified for this subset unless it was apparent that disease
would be left behind. However, the description of the ran-
domization method in these three studies is insufficient ac-
cording to the recent CONSORT statement (Table 1).39 Col-
lectively, whether lymph node dissection has a survival
benefit is still unknown.
Who Can Attain Oncological Benefit from
Lymph Node Dissection?
The most frequent relapse pattern after complete resec-
tion for lung cancer surgery is distant metastasis, even in
stage I patients,35,40 due to a distant micrometastasis that
already existed at the time of surgery. Since lymph node
dissection is a therapy used to achieve a better local control of
cancer, this procedure does not improve the survival of the
patient with distant metastasis. Moreover, in the patient who
has no nodal metastasis, lymph node dissection has no impact
on survival and can just prove the pathologic N0 status.
Therefore, the patients who can obtain oncological benefit
from nodal dissection would be those who have resectable
pN2 and no distant micrometastasis, who may comprise a
small group of patients with lung cancer.
Is it Possible to Conduct a Clinical Trial to
Clear the Oncological Significance of Lymph
Node Dissection?
Among patients with N2 disease, two types of nodal
metastasis exist, the preoperatively diagnosed N2 disease
(cN2-pN2) and postoperatively proven N2 disease (cN0,
1-pN2). The cN2-pN2 disease showed dismal prognosis of
less than 10% of a 3-year survival after pulmonary resec-
tion.40,41 The standard of care for cN2 disease is a chemora-
diotherapy, and the role of surgery for this subset is currently
unknown as described in the IASLC consensus report.42 The
patient who can attain oncological benefit from lymph node
dissection should be the patient with cN0, 1-pN2 disease, i.e.,
“microscopic N2 disease.”43–45
However, preoperatively recognizing and randomizing
the patients with microscopic N2 is difficult because these
patients can be identified mostly after completing the nodal
dissection and pathologic examination.28,46–49 Therefore, if a
surgeon wants to demonstrate the oncological benefit of
lymph node dissection in a RCT, extremely large numbers of
patients must be enrolled in the study.
Again, thus far, the oncological benefit of lymph node
dissection has not been demonstrated. To establish the sur-
vival benefit of nodal dissection in lung cancer surgery will
be very difficult because of the difficulty in carrying out this
sort of large RCT study and the lack of appropriate method-
ology. The American College of Surgery Oncology Group
Z0030 study, which is a multi-institutional prospective ran-
domized trial designed to compare the long-term survival
after SND and sampling, may clear up this issue in the future.
The Concept and Technique of Lymph Node
Dissection
At the time of pulmonary resection, evaluation of nodal
status is performed before making any decision as to resect-
ability.4 As a first step, all ipsilateral hilar and mediastinal
nodal stations are checked immediately after thoracotomy.
The macroscopic appearance or internal architecture of the
nodes is assessed by the surgeon, and if necessary, examining
frozen sections of key nodes is performed. This evaluation is
then repeated for the N1 nodes, extending peripherally in a
centrifugal fashion until the surgeon believes that sufficient
information has been gathered to decide as to the desirability
of resection and the extent required.4 This allows the surgeon
to assess the feasibility and advisability of complete clearance
before commencing resection.
In terms of technical aspect, SND is carried out by
excising all tissue in the compartment surrounded by some
anatomic structures with scissors or electrocautery. This pro-
cedure is similar to the one previously reported by Cahan in
1951.1 As shown in Figure 2, en block removal of all tissue
that may contain cancer cells, including lymph nodes and
surrounding fatty tissue within anatomic landmarks, as well
as the trachea, bronchus, superior vena cava, and the aorta
and its branches, pulmonary vessels, and pericardium, should
be performed. Special care must be taken not to interrupt the
lymphatic vessels or disrupt the lymph node itself. In addi-
tion, ligating the connective tissue, which may include the
small lymphatic vessels, is sometimes necessary to prevent
postoperative chylothorax.
There have been reported alternative techniques for
SND. Witte and Hu¨rtgen50 reported video-assisted mediasti-
noscopic lymphadenectomy technique with two-bladed
spreadable videomediastinoscope. They concluded that accu-
racy and radicality of video-assisted mediastinoscopic lymph-
adenectomy could equal those of open lymphadenectomy.
Zielin´ski51 demonstrated transcervical extended mediastinal
lymphadenectomy procedure through 5 to 8 cm collar inci-
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sion in the neck. This technique enabled complete removal of
all mediastinal nodal stations except for the pulmonary liga-
ment nodes and the most distal left paratracheal nodes.
Zielin´ski52 also reported the new technique of transcervical
right upper lobectomy with transcervical extended mediasti-
nal lymphadenectomy.
The Extent of Lymph Node Dissection
The extent of lymph node dissection for lung cancer has
changed little since Cahan reported “radical lobectomy” in
1960.2 SND involves the identification of nodal stations and
their labeling in accordance with an internationally recog-
nized nodal chart. Several lymph node maps have been
proposed,53,54 each with its advantages and disadvantages.55
The one most widely used is that proposed by Naruke in
1978.53 The Japan Lung Cancer Society published the de-
tailed definitions of each nodal station, providing a definition
for each station based on CT and surgical findings, and was
intended for clinical use. The map has been used mostly in
Japan because the explanatory manual only became available
in English in 2000.56
In 1997, Mountain and Dresler54 published the new
map, which has been widely favored by the American Tho-
racic Society and the European Respiratory Society, among
others.57–59 This map is included in the American Joint
Committee on Cancer handbook and in the Union Internatio-
nale Contre le Cancer tumor node metastasis atlas.60 With
these maps, extensive nodal dissection, including the superior
and inferior mediastinum (i.e., SND), has been universally
performed in lung cancer surgery.6,7,61
The lobe-specific patterns of nodal metastases have
become recognized due to increasing analyses of the lymph
node metastatic pathway. Asamura et al.62 and Okada et al.63
reported that right upper lobe tumors and left upper segment
tumors tend to metastasize to the superior mediastinum, but
rarely metastasize to the subcarinal nodes without concomi-
tant metastasis to the hilar or superior mediastinal nodes. In
addition, Okada et al.63 suggested that lower lobe tumors
seldom metastasize to the superior mediastinal nodes without
concomitant metastasis to the hilar or subcarinal nodes.
Considering the results of lobe-specific patterns of nodal
metastases, the preoperative evaluation of the nodal status
and strategy of nodal dissection has been changing, especially
in stage I lung cancer (Table 2).64–67 As the detection of early
lung cancer is increasing, the extent of nodal dissection
should be tailored by considering, for example, the tumor
location, tumor size, cell type, and percentage of ground glass
opacity area on CT scan in each tumor. This type of tailored
dissection was termed “lobe-specific SND” by European
Society of Thoracic Surgeons guidelines.4 For lobe-specific
SND, the “key nodes,” which are easily sampled and checked
during surgery by examining frozen sections, has been ex-
plored in each lobe tumor.62–67 The definition of complete
resection for lung cancer proposed by a subcommittee of
IASLC staging committee includes the requirements of no
residual tumor after SND or lobe-specific SND.68
Summary
Although clear evidence regarding the survival benefit
of lymph node dissection for lung cancer is lacking, lobec-
tomy with lymph node dissection has been a standard surgical
procedure for lung cancer. It will take more several years to
obtain the final results of the ACOSOG Z0030 randomized
trial to establish whether SND will improve patient survival.
However, SND remains an important investigative process in
staging patients and takes just within 30 minutes40,69; more-
over, the initial results of ACOSOG Z0030 randomized trial
found no increase in morbidity or mortality from lymph node
dissection.70 Thus, little benefit seems to currently exist in
limiting nodal dissection.
TABLE 2. The Strategy of Selective Nodal Dissection Based
on Lobe-Specific Patterns of Nodal Spread
Location of the Primary Tumor
Extent of Nodal
Dissection
RUL
LUL-Superior
Segment
RML
LUL-Lingular
Segment
RLL
LLL
Superior mediastinal nodes Advisable Advisable Not always
necessarya
Inferior mediastinal nodes
Subcarinal node (#7) Not always
necessaryb
Advisable Advisable
Paraesophageal node
(#8) and pulmonary
ligament node (#9)
Unnecessary Unnecessary Advisable
a May be unnecessary when hilar and subcarinal (#7) nodes are negative on frozen
section.
b May be unnecessary when hilar and superior mediastinal nodes are negative on
frozen section.
RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left
upper lobe; LLL, left lower lobe.
FIGURE 2. Photographs after completing
systematic nodal dissection of the right superior
mediastinum. A, Removed lymph nodes and
surrounding fatty tissue en block within anatomic
landmarks. B, Skeletonized anatomic structures
after systematic nodal dissection. SVC, superior
vena cava; Tr. Sup., superior trunk of the right
pulmonary artery; RBCV, right brachiocephalic
vein; LBCV, left brachiocephalic vein; RBCA, right
brachiocephalic artery.
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